Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma
Our findings are of interest to readers because they bring new evidence that small-molecule CCR4 antagonists may be an alternative therapeutic strategy to target CCR4+ CTCL cells. They may inhibit CCR4 function but not eradicate cells, so the side effects may be avoided or minimized.
Authors
- Loka Reddy Velatooru (ORCID: https://orcid.org/0000-0003-1451-6879)
- Pedram Bijani (ORCID: https://orcid.org/0000-0001-8439-3179)
- Wei Han (ORCID: https://orcid.org/0009-0000-0744-5668)
- José S. Enriquez (ORCID: https://orcid.org/0000-0002-9119-8176)
- Xiaohong Wang (ORCID: https://orcid.org/0000-0002-2700-092X)
- Xiao Ni (ORCID: https://orcid.org/0000-0002-0154-446X)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0297
- Citations
- 1
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.53